Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 111 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR How I Found a Meaningful Career After Cancer October 26, 2020 Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... January 26, 2022 A coming together of minds for early detection August 18, 2022 First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... December 4, 2023 Load more HOT NEWS FDA Approves New and Updated Indications for Temozolomide Under Project Renewal Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... New on NCI’s Websites for November 2024
